SCHEMBL18209347

SCHEMBL18209347

COc1ccc(-n2c3ccccc3c3ccccc32)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ MAPK1 P28482 3/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ GAA P10253 1/20 0.47
▸ BRD9 Q9H8M2 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.45
▸ TUBB4A P04350 1/20 0.44
▸ TUBB P07437 1/20 0.44
▸ TUBA3C P0DPH7 1/20 0.44
▸ TUBA1B P68363 1/20 0.44
▸ TUBA4A P68366 1/20 0.44
▸ TUBB4B P68371 1/20 0.44
▸ TUBB3 Q13509 1/20 0.44
▸ TUBB2A Q13885 1/20 0.44
▸ TUBB8 Q3ZCM7 1/20 0.44
▸ TUBA3E Q6PEY2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10100811 0.88 KDM4E (0.47) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL31495214 0.87 TUBB4A (0.49) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL14648914 0.86 SMN1; SMN2 (0.44) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL28001656 0.85 SMN1; SMN2 (0.47) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL16521616 0.85 IDO1 (0.47) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL14039032 0.83 ENPP2 (0.49) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL14019103 0.81 MAPT (0.56) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL13049622 0.79 KDM4E (0.39) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL16900164 0.78 SMN1; SMN2 (0.42) SMN1; SMN2MAPK1L3MBTL1KDM4EATM
SCHEMBL18780394 0.78 L3MBTL1 (0.38) SMN1; SMN2MAPK1L3MBTL1KDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180138407-A1 FOUR-COORDINATE BORON COMPOUNDS DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-17 — — US disclosed
US-20180138407-A1 FOUR-COORDINATE BORON COMPOUNDS DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-17 — — US disclosed
US-20180138407-A1 FOUR-COORDINATE BORON COMPOUNDS DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-17 — — US disclosed
EP-3288951-A1 FOUR-COORDINATE BORON COMPOUNDS Dow Global Technologies LLC (US) 2018-03-07 — — EP disclosed
WO-2016178827-A1 FOUR-COORDINATE BORON COMPOUNDS DOW GLOBAL TECHNOLOGIES LLC (US) 2016-11-10 — — WO disclosed
WO-2016178827-A1 FOUR-COORDINATE BORON COMPOUNDS DOW GLOBAL TECHNOLOGIES LLC (US) 2016-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180138407-A1 FOUR-COORDINATE BORON COMPOUNDS C5, RBBP5, C2CD5 SMN1; SMN2 2038/4885MAPK1 1423/4885L3MBTL1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback